Summit Therapeutics Publishes Scientific Updates to Corporate Website
06 mai 2021 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our...
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
05 mai 2021 12h47 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...
Summit Therapeutics Announces Commencement of Rights Offering
21 avr. 2021 08h04 HE
|
Summit Therapeutics Inc.
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Summit Therapeutics Announces Rights Offering
26 mars 2021 07h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the...
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
12 nov. 2020 12h30 HE
|
Deinove
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...
Summit Announces Results of Court Meeting and General Meeting
19 août 2020 16h01 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc...
Summit Announces Intention to Redomicile its Holding Company to the United States
16 juil. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA, US, July 16, 2020 –...
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
13 juil. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020...
Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
30 avr. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational...
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
21 déc. 2017 02h00 HE
|
Summit Therapeutics plc
Summit to receive $2.5 million upfront paymentUp to $25 million in development, regulatory, pricing and initial sales milestonesSummit retains commercial rights to ridinilazole in rest of the world ...